Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
documentation of a diagnosis of active acromegaly based on either of the following definitions:
1. the patient has never received somatostatin analog nor dopaminergic agonist or had previously received this medication but had stopped more than 3 months before visit 1 and had a mean growth hormone (GH)level \>5ng/mL at visit 1; or
2. the patient was receiving treatment with a somatostatin analog (other than lanreotide autogel) or a dopaminergic agonist at visit 1, had a mean GH \>3ng/mL at visit 2 (or visit 2a) and had at least a 100% increase in mean GH levels between visit 1 and visit 2 (or visit 2a)
You may not be if
receipt of radiotherapy for acromegaly within 3 years
pituitary surgery within 3 months prior to visit 1
prior receipt of lanreotide autogel or GH antagonist
anticipated need for pituitary surgery (adenomectomy) or radiotherapy during the study period
known hypersensitivity to any of the test materials or related compounds
clinically significant renal or hepatic abnormalities
Clareo Health | Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
